Lilly shuffles marketing personnel

Share this article:
Lilly shuffles marketing personnel
Lilly shuffles marketing personnel
Eli Lilly will consolidate its global and international marketing organizations as the drugmaker undergoes a companywide initiative to reduce management layers.

Under the plan, Dan Hasler, former VP of global brands, will assume the role of VP of the newly formed marketing organization, Lilly said in a statement issued today.

Exiting Lilly is Rich Pilnik, former VP and chief marketing officer.

Pilnik retires following a 25 year career with the Indianapolis-based drugmaker. He twice served as the company's chief marketing officer--from 1998 to 2001 and from 2006 to present--and also recently served as president of Lilly Europe.

Meanwhile, Nancy Lilly, former VP of US sales and marketing for specialty products, has been named VP of new product planning and market analytics.

These executive level changes are effective immediately, Lilly said, with the new structure to be fully in place by July 1.

“These leadership changes will help to strengthen key aspects of Lilly's operations as we also develop the next generation of leadership for the company,” CEO John Lechleiter said in a statement.

Lechleiter today also called for changes to Lilly's R&D, international operations and US operations divisions.

Further details can be found by logging on to: http://newsroom.lilly.com/ReleaseDetail.cfm?ReleaseID=311669.
Share this article:
close

Next Article in News

Email Newsletters

More in News

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.